Evidence map›Paper›PMID 36247773›Full record

ArticleFrontiers in neurology2022

Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria.

Amelie S Lotz-Havla, Sabrina Katzdobler, Brigitte Nuscher, Katharina Weiß, Johannes Levin, Joachim Havla, Esther M Maier

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Amelie S Lotz-HavlaDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
Sabrina KatzdoblerDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Brigitte NuscherDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Katharina WeißDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
Johannes LevinDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Joachim HavlaInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Esther M MaierDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
LMU Klinikum · DELudwig-Maximilians-Universität München · DEMunich Cluster for Systems Neurology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To pave the way for healthy aging in early treated phenylketonuria (ETPKU) patients, a better understanding of the neurological course in this population is needed, requiring easy accessible biomarkers to monitor neurological disease progression in large cohorts. The objective of this pilot study was to investigate the potential of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as blood biomarkers to indicate changes of the central nervous system in ETPKU. In this single-center cross-sectional study, GFAP and NfL concentrations in serum were quantified using the Simoa

Indexed as

biomarkers brain alterationsglial alterationsglial fibrillary acidic protein (GFAP)neuroaxonal damageneurofilament light chain (NFL)optical coherence tomographyphenylketonuria (PKU)Simoa assay

Identifiers

PMID36247773
PMCPMC9559705
OpenAlexW4297996042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.